Drug Trial Radar · NCT05007782
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
304
Actual
Start
Aug 18, 2021
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Aug 16, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human (FIH) study to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of denikitug (also known as GS-1811) as monotherapy and in combination with zimberelimab in participants with advanced solid tumors. This study will be conducted in 6 parts (Parts A, B, and E: monotherapy, Parts C and D: combination therapy, and Part F for both monotherapy and combination therapy) in participants with advanced solid tumors who have received, been intolerant to, or been ineligible for all treatments known to confer clinical benefit or in participants with select solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
DenikitugDrug
Administered Intravenously
ZimberelimabDrug
Administered Intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs) in Part A and CTime frame: Day 1 Through Day 21
- Percentage of Participants Experiencing Adverse Events (AEs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0Time frame: First dose to End of Treatment (up to 12 months for monotherapy and 24 months for combination therapy) plus 90 days
- Percentage of Participants Experiencing Laboratory Abnormalities According to the NCI CTCAE v5.0Time frame: First dose to End of Treatment (up to 12 months for monotherapy and 24 months for combination therapy) plus 90 days
Locations
25 sites in 5 countries. Site status is shown where the registry gives one.
University of California San Diego
La Jolla, California
Stanford Cancer Center
Palo Alto, California
Smilow Cancer Center
New Haven, Connecticut
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Tennessee Oncology, PLLC
Nashville, Tennessee
University of Texas Southwestern Medical Center
Dallas, Texas
Sarah Cannon Research Institute at Mary Crowley
Dallas, Texas
MD Anderson Cancer Center
Houston, Texas
NEXT Oncology
San Antonio, Texas
University of Wisconsin Clinical Sciences Center
Madison, Wisconsin
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia
Monash Medical Centre
Clayton, Victoria, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
University Health Network, Princess Margaret Cancer Centre
Toronto, Canada
Hospital Universitari Vall d´Hebrón
Barcelona, Spain
MD Anderson Cancer Center
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario Quironsalud Madrid
Madrid, Spain
Clinica Universidad de Navarra
Pamplona, Spain
Changhua Christian Hospital
Changhua, Taiwan
Chi Mei Hospital, Liouying
Tainan, Taiwan
National Taiwan University Cancer Center (NTUCC)
Taipei, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
Chang Gung Medical Foundation Linkou Chang Gung Memorial Hospital
Taoyuan City, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.